X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1671) 1671
Publication (82) 82
Book Chapter (17) 17
Conference Proceeding (14) 14
Patent (11) 11
Book Review (5) 5
Web Resource (2) 2
Book / eBook (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (707) 707
male (402) 402
female (375) 375
middle aged (335) 335
adult (317) 317
gastroenterology & hepatology (307) 307
gastroenterology and hepatology (272) 272
index medicus (191) 191
aged (175) 175
treatment outcome (104) 104
antiviral agents - therapeutic use (93) 93
adolescent (81) 81
infection (75) 75
therapy (74) 74
follow-up studies (72) 72
animals (69) 69
medicine, general & internal (68) 68
prevalence (68) 68
helicobacter pylori (66) 66
chronic disease (65) 65
surgery (65) 65
cirrhosis (62) 62
retrospective studies (62) 62
liver cirrhosis (60) 60
interferon (57) 57
drug therapy, combination (56) 56
interferon-alpha - therapeutic use (56) 56
risk factors (56) 56
hepatitis (55) 55
hepatitis c, chronic - drug therapy (54) 54
italy (54) 54
time factors (53) 53
liver transplantation (52) 52
hepacivirus - genetics (50) 50
hepatitis c virus (50) 50
prognosis (49) 49
hepatitis b surface antigens - analysis (48) 48
hepatitis c (48) 48
genotype (47) 47
hepatitis b - immunology (47) 47
liver (47) 47
prospective studies (47) 47
biopsy (46) 46
liver - pathology (46) 46
analysis (44) 44
disease (43) 43
health aspects (43) 43
virology (42) 42
immunology (41) 41
infectious diseases (41) 41
recombinant proteins (41) 41
transplantation (41) 41
aged, 80 and over (40) 40
hepatitis b (40) 40
hepatitis b virus - genetics (39) 39
ribavirin - therapeutic use (39) 39
hepatitis b - complications (38) 38
rna, viral - blood (38) 38
hepatitis delta virus - immunology (37) 37
medicine & public health (37) 37
pharmacology & pharmacy (37) 37
recurrence (37) 37
antiviral agents - adverse effects (36) 36
hepatitis delta antigens (36) 36
gastroenterology (34) 34
helicobacter infections - complications (34) 34
hepatitis b virus (34) 34
ribavirin (34) 34
hepatitis delta virus - genetics (33) 33
virus-infection (33) 33
child (31) 31
fluorescent antibody technique (31) 31
hepatitis b, chronic - drug therapy (31) 31
care and treatment (30) 30
hepatocellular-carcinoma (30) 30
management (30) 30
antibodies (29) 29
hepatitis c, chronic - virology (29) 29
italy - epidemiology (29) 29
lamivudine (29) 29
liver - immunology (29) 29
liver cirrhosis - complications (29) 29
antiviral agents - administration & dosage (28) 28
epidemiology (28) 28
hepatitis c, chronic - complications (28) 28
rna, viral - analysis (28) 28
antiviral agents (27) 27
diagnosis (27) 27
hepatitis b antigens - analysis (27) 27
hepatitis d - epidemiology (27) 27
oncology (27) 27
viral load (27) 27
case-control studies (26) 26
interferons - therapeutic use (26) 26
lamivudine - therapeutic use (26) 26
risk (26) 26
polyethylene glycols - therapeutic use (25) 25
rna (25) 25
virus (25) 25
association (24) 24
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 685 - 697
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1195 - 1206
Journal Article
Journal Article
by Gustot, Thierry and Fernandez, Javier and Garcia, Elisabet and Morando, Filippo and Caraceni, Paolo and Alessandria, Carlo and Laleman, Wim and Trebicka, Jonel and Elkrief, Laure and Hopf, Corinna and Solís‐Munoz, Pablo and Saliba, Faouzi and Zeuzem, Stefan and Albillos, Augustin and Benten, Daniel and Montero‐Alvarez, José Luis and Chivas, Maria Teresa and Concepción, Mar and Córdoba, Juan and McCormick, Aiden and Stauber, Rudolf and Vogel, Wolfgang and de Gottardi, Andrea and Welzel, Tania M and Domenicali, Marco and Risso, Alessandro and Wendon, Julia and Deulofeu, Carme and Angeli, Paolo and Durand, François and Pavesi, Marco and Gerbes, Alexander and Jalan, Rajiv and Moreau, Richard and Ginés, Pere and Bernardi, Mauro and Arroyo, Vicente and Aguilar‐Melero, P and Bañares, R and Bocci, M and Catalina, MV and Chin, JL and Coenraad, MJ and Coilly, A and Dorn, L and Gatta, A and Gerber, L and Grøenbæk, H and Graupera, I and Guevara, M and Hausen, A and Karlsen, S and Lohse, AW and Maggioli, C and Markwardt, D and Martinez, J and Marzano, A and de la Mata García, M and Mesonero, F and Mookerjee, RP and Moreno, C and Morrell, B and Mortensen, C and Nevens, F and Peck‐Radosavljevic, M and Rizzetto, M and Romano, A and Samuel, D and Sauerbruch, T and Simon‐Talero, M and Solà, E and Soriano, G and Sperl, J and Spindelboeck, W and Steib, C and Valla, D and Verbeke, L and Van Vlierberghe, H and Wege, H and Willars, C and Baenas, MY and Zaccherini, G and CANONIC Study Investigators EASL-C and CANONIC Study Investigators of the EASL-CLIF Consortium
Hepatology, ISSN 0270-9139, 07/2015, Volume 62, Issue 1, pp. 243 - 252
Journal Article
Liver Transplantation, ISSN 1527-6465, 03/2007, Volume 13, Issue 3, pp. 349 - 360
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
GENETIC-VARIATION | IL28B | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 03/2013, Volume 57, Issue 3, pp. 974 - 984
Journal Article